We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development.
Find more details at our careers page....
Physiomics plc is pleased to announce that it has been awarded a contract by a new major pharmaceutical client. The project, which is expected to be completed during the Company's current financial year involves the use of Physiomics' Virtual Tumour technology in a pre-clinical setting and its value is approximately £35k.
Click here to read in full...
The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:
Click here to read more....
Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the “Options Shares”) have now been issued to the following employees at the following exercise prices:
Please click here to read more....
Following the movement in the Physiomics share price today the Company would like to draw investors’ attention to its RNS of the 28th of November in which the Company announced the signing of a Master Services Agreement (“Agreement”) with Merck KGaA whose minimum value in the first twelve months of the contract is €500,000 (equivalent to around 60% of our net operating expenses for the...
